ArticleDocumenta ophthalmologica. Advances in ophthalmology2026
Clinical course of a patient with PRSS56-associated nanophthalmos (isolated microphthalmia) and uveal effusion syndrome.
Article in Documenta ophthalmologica. Advances in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo describe the detailed clinical course and genetic findings of a Japanese patient with nanophthalmos (isolated microphthalmia) who developed bilateral uveal effusion syndrome (UES). CASE REPORT: A 50-year-old Japanese man presented with distorted and decreased vision in his right eye. Ophthalmoscopy revealed non-rhegmatogenous retinal detachment with shifting subretinal fluid. The horizontal corneal diameter was 11.5 mm in both eyes, while the axial lengths were 15.6 and 15.3 mm in the right and left eyes, respectively, confirming the diagnosis of nanophthalmos (microphthalmia)-associated UES. After steroid pulse therapy followed by sclerectomy with vortex vein decompression (S-VVD), the UES resolved 10 months postoperatively. The eyes remained stable for 15 years, after which the patient developed bilateral cataracts and elevated intraocular pressure. Cataract surgery was done uneventfully, but signs of UES appeared in the left eye five days postoperatively. This was controlled with multiple treatments, including steroid pulse therapy, intravitreal anti VEGF injection, and oral carbonic anhydrase inhibitor. However, UES recurred after five months. S-VVD and vitrectomy with silicone oil tamponade were performed, and the UES resolved after one year postoperatively. Ultimately, electroretinography (ERG) became non-recordable, and the visual fields were constricted in both eyes. Whole-exome sequencing identified a previously unreported homozygous nonsense variant in PRSS56 (c.202C>T, p.Arg68Ter), classified as pathogenic based on the ACMG criteria.
conclusionsThis report describes a patient with an unreported pathogenic PRSS56 variant who exhibited a typical and severe course of nanophthalmos (isolated microphthalmia) complicated by bilateral UES. Although the effusions eventually resolved after multiple interventions, the prolonged UES was challenging to manage and resulted in irreversible retinal dysfunction with a non-recordable ERG.
Indexed as
Identifiers
42321572What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.